Condensed Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2025	Dec. 31, 2024
Current assets
Cash and cash equivalents	$ 36,810	$ 35,627
Marketable securities, short-term	106,559	135,930
Prepaid expenses and other current assets	5,035	6,749
Total current assets	148,404	178,306
Marketable securities, long-term	22,797	59,968
Restricted cash	232	232
Other assets, long-term	464	486
Total assets	171,897	238,992
Current liabilities
Accounts payable	2,103	5,648
Accrued clinical trial expenses	11,108	15,344
Accrued expenses and other current liabilities	11,650	6,615
Total current liabilities	24,861	27,607
Debt, long-term	29,882	29,419
Other liabilities, long-term	77	150
Total liabilities	54,820	57,176
Commitments and contingencies (Note 10)
Stockholders’ equity
Preferred stock, $0.0001 par value; 10,000,000 shares authorized and no shares issued and outstanding as of June 30, 2025 and December 31, 2024	0	0
Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2025 and December 31, 2024; 60,573,425 and 60,094,083 shares issued and outstanding as of June 30, 2025 and December 31, 2024, respectively	6	6
Additional paid-in capital	511,921	506,985
Accumulated deficit	(394,873)	(325,127)
Accumulated other comprehensive income (loss)	23	(48)
Total stockholders’ equity	117,077	181,816
Total liabilities and stockholders’ equity	$ 171,897	$ 238,992